Drugwrite LLC, a company that provides offshore services in medical communications, clinical data management, Life sciences marketing and information technology. Our clientele includes top notch life sciences companies across the globe.

Thursday, May 6, 2010

What are your thoughts of OFFSHORING MEDICAL COMMUNICATION from India?


It has been a month since my last post and I have had a number of new business projects related to medical communications.
Each week I will be posting new information and articles in Medical Communication services field.
This is a very good time for IT health care and Medical Communication companies due to new media and communication channels made possible by the digital age. It is a win -win situation for all healthcare communication companies which could leverage the right technologies with the right resources.
India is being considered a favored destination for medical writing because India has a great pool of qualified, talented and experienced medical scientists. Every year, approximately three million of students are produced from the scientific stream. Many of them have thorough knowledge of good clinical practices, drug development, experience with basic and clinical sciences and good writing skills. Many of them also possess industry experience and consequently know how to make good reports and analyze data. Moreover English is the primary language and they can communicate to produce scientific documents that are of good quality.
Due to the cost effectiveness and competitiveness, India is being considered as a favorable destination for medical writing and other CRO services that are needed to fuel the growth of the biopharma segment. Indian professionals have already made their mark in Information Technology and now the world is looking at us to be a partner in Clinical Research, Medical Writing, Development, review, and editing of technical documents that include clinical study protocols, investigator's brochures, study reports, risk assessments, presentations, and regulatory submissions in relation to the safety evaluation of ophthalmic devices.
Please provide any suggestions that you may have.
Amrin Kausar
732-543-7647